It's time to propose a uniform criteria for determining "clinical complete response" in hepatocellular carcinoma.
作者信息
Zhao Lei, Zhao Haitao, Sun Huichuan
机构信息
Department of HPB Surgery, Shandong Cancer Hospital Affiliated to Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China.
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
出版信息
Hepatobiliary Surg Nutr. 2022 Aug;11(4):620-622. doi: 10.21037/hbsn-22-233.
Abstract
摘要
相似文献
1
It's time to propose a uniform criteria for determining "clinical complete response" in hepatocellular carcinoma.现在是时候提出一套统一的标准来判定肝细胞癌的“临床完全缓解”了。
Hepatobiliary Surg Nutr. 2022 Aug;11(4):620-622. doi: 10.21037/hbsn-22-233.
2
[Comparative studies on the banding characteristics of insulin receptor in human hepatocellular carcinoma and adjacent liver tissues].[人肝癌组织与癌旁肝组织胰岛素受体带型特征的比较研究]
Hua Xi Yi Ke Da Xue Xue Bao. 2002 Jan;33(1):32-4.
3
[Expression of phosphofructokinase 1 protein and it's enzyme activity on nasopharyngeal carcinoma].[磷酸果糖激酶1蛋白在鼻咽癌中的表达及其酶活性]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015 Aug;29(16):1455-7.
4
"It's not rocket science" and "It's not brain surgery"-"It's a walk in the park": prospective comparative study.“这不是火箭科学”和“这不是脑外科手术”-“这是小菜一碟”：前瞻性比较研究。
BMJ. 2021 Dec 13;375:e067883. doi: 10.1136/bmj-2021-067883.
5
The last taboo. It's not sex. It's not drinking. It's stress--and it's soaring.最后的禁忌。不是性。不是饮酒。是压力——而且压力正在飙升。
Fortune. 2002 Oct 28;146(8):136-8, 140, 142 passim.
6
"Day-to-day, it's a roller coaster. It's frustrating. It's rewarding. It's maddening and it's enjoyable": A qualitative investigation of the lived experiences of addiction counselors.“日复一日，这就像坐过山车。既令人沮丧，又有回报；既让人抓狂，又令人愉悦”：对成瘾咨询师生活经历的定性研究。
Psychol Serv. 2021 Aug;18(3):287-294. doi: 10.1037/ser0000394. Epub 2019 Oct 3.
7
It's me grandma! it's me! Eileen Mitchell It's me grandma! it's me! Alzheimer's Society £4.95 20pp 9781906647117 Product code 1004 [Formula: see text].是我，奶奶！是我！艾琳·米切尔 是我，奶奶！是我！阿尔茨海默病协会 4.95英镑 20页 9781906647117 产品代码1004 [配方：见正文]
Nurs Older People. 2011 Sep 1;23(7):8. doi: 10.7748/nop.23.7.8.s3.
8
It's a moth! It's a butterfly! It's the complete mitochondrial genome of the American moth-butterfly (Warren, 1897) (Insecta: Lepidoptera: Hedylidae)!这是一只蛾！这是一只蝴蝶！这是美洲蛾蝶（沃伦，1897年）（昆虫纲：鳞翅目：蛱蝶科）的完整线粒体基因组！
Mitochondrial DNA B Resour. 2020 Oct 27;5(3):3633-3635. doi: 10.1080/23802359.2020.1831991.
9
Calcium in the heart: when it's good, it's very very good, but when it's bad, it's horrid.心脏中的钙：当它发挥有益作用时，效果非常好，但当它产生不良影响时，情况就很糟糕了。
Biochem Soc Trans. 2007 Nov;35(Pt 5):957-61. doi: 10.1042/BST0350957.
引用本文的文献
1
Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy.三联疗法转化后初始不可切除肝细胞癌患者临床完全缓解的预后价值
Liver Cancer. 2025 Jan 21;14(4):420-434. doi: 10.1159/000543602. eCollection 2025 Aug.
2
Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma.应对复杂性：晚期肝细胞癌转化治疗中的挑战与机遇
Clin Exp Med. 2025 May 18;25(1):169. doi: 10.1007/s10238-025-01698-9.
3
Radiologic complete response after conversion therapy for hepatocellular carcinoma: is liver transplantation necessary?肝细胞癌转化治疗后的放射学完全缓解：是否需要肝移植？
Hepatobiliary Surg Nutr. 2025 Apr 1;14(2):351-354. doi: 10.21037/hbsn-2024-702. Epub 2025 Mar 21.
4
Clinical study on conversion therapy of hepatocellular carcinoma - summary and comparison of clinical data from a single center of consecutive four years.肝细胞癌转化治疗的临床研究-连续四年单中心临床资料总结与比较。
BMC Gastroenterol. 2024 Oct 17;24(1):369. doi: 10.1186/s12876-024-03457-8.
5
Real-world practice of conversion surgery for unresectable hepatocellular carcinoma - a single center data of 26 consecutive patients.不可切除肝细胞癌转化手术的真实世界实践-单中心 26 例连续患者数据。
BMC Cancer. 2023 May 20;23(1):465. doi: 10.1186/s12885-023-10955-7.
本文引用的文献
1
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).《肝细胞癌转化治疗中国专家共识（2021年版）》
Hepatobiliary Surg Nutr. 2022 Apr;11(2):227-252. doi: 10.21037/hbsn-21-328.
2
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.可切除肝细胞癌中围手术期纳武单抗单药治疗与纳武单抗联合伊匹单抗治疗的随机、开放标签、2 期临床试验。
Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218. doi: 10.1016/S2468-1253(21)00427-1. Epub 2022 Jan 20.
3
Assessment of clinical and pathological complete response after neoadjuvant chemoradiotherapy in rectal adenocarcinoma and its therapeutic implications.评估新辅助放化疗后直肠腺癌的临床和病理完全缓解及其治疗意义。
Rom J Morphol Embryol. 2021 Apr-Jun;62(2):411-425. doi: 10.47162/RJME.62.2.07.
4
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer.国际共识推荐意见：直肠癌患者接受（放）化疗后器官保存的关键结局指标
Nat Rev Clin Oncol. 2021 Dec;18(12):805-816. doi: 10.1038/s41571-021-00538-5. Epub 2021 Aug 4.
5
Conversion surgery for hepatocellular carcinoma in the new era of targeted and immune checkpoint inhibitor therapies.靶向和免疫检查点抑制剂治疗新时代下肝细胞癌的转化手术
Hepatobiliary Surg Nutr. 2020 Dec;9(6):809-811. doi: 10.21037/hbsn-20-693.
6
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
7
Comparison of Outcome of Esophagectomy Versus Nonsurgical Treatment for Resectable Esophageal Cancer with Clinical Complete Response to Neoadjuvant Therapy.新辅助治疗后临床完全缓解的可切除食管癌行手术与非手术治疗的结局比较。
Ann Surg Oncol. 2018 Aug;25(8):2428-2433. doi: 10.1245/s10434-018-6437-2. Epub 2018 Mar 21.
8
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.改良版 RECIST（mRECIST）用于肝细胞癌的评估。
Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19.
9
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准：修订的RECIST指南（第1.1版）
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
Zotero 插件